La cadena de opciones muestra datos clave de las opciones de acciones de 60 Degrees a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para 60 Degrees..

60 Degrees (NASDAQ:SXTP) Bolsa, Cadena de Opciones

60 Degrees

60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.

60 Degrees Pharmaceuticals, Inc. - Common Stock

60 Degrees Pharmaceuticals Inc

60 Degrees Pharmaceuticals, Inc. - Warrant

Guggenheim maintains Performance Food Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFGC#NYSE">PFGC</a>) with a Buy and raises the price target from $90 to $95.

News

Price Target

Analyst Ratings

PFGC

Guggenheim Maintains Buy on Performance Food Gr, Raises Price Target to $95

Macquarie analyst Tim Nollen maintains DoubleVerify Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DV#NYSE">DV</a>) with a Outperform and maintains $19 price target.

Macquarie Maintains Outperform on DoubleVerify Hldgs, Maintains $19 Price Target

Morgan Stanley analyst Bob Huang maintains Allstate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>) with a Overweight and raises the price target from $220 to $228.

Morgan Stanley Maintains Overweight on Allstate, Raises Price Target to $228

Guggenheim analyst Debjit Chattopadhyay maintains Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) with a Buy and raises the price target from $13 to $15.

FOLD

Guggenheim Maintains Buy on Amicus Therapeutics, Raises Price Target to $15

Applovin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) stock shot higher on Thursday following the upbeat quarterly print.
On Wednesday, the company reported <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41791722/applovin-stock-soars-after-q3-earnings-report-revenue-beat-eps-beat-strong-software-platform-growth" rel="noreferrer noopener">third-quarter revenue</a> of $1.2 billion, up 39%, beating analyst&nbsp;consensus estimates of $1.13 billion. Applovin increased the company&#8217;s share repurchase program by $2 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41809105/warner-bros-discovery-q3-earnings-olympics-and-blockbusters-drive-gains-ceo-highlights-subscriber-s" rel="noreferrer noopener">Warner Bros. Discovery Q3 Earnings: Olympics and Blockbusters Drive Gains, CEO Highlights Subscriber Surge and New Partnerships</a>
It expects fourth-quarter revenue of $1.24 billion—$1.26 billion.
Multiple Wall Street analysts rerated the stock after the quarterly results.
JP Morgan analyst Cory Carpenter maintained AppLovin with a Neutral and raised the <a target="_blank" href="https://www.benzinga.com/quote/APP/analyst-ratings" rel="noreferrer noopener">price target from&nbsp;$160&nbsp;to&nbsp;$200</a>.
Needham analyst Bernie McTernan reiterated AppLovin with a Hold.
Benchmark analyst Mark Zgutowicz maintained AppLovin with a Sell and a $66&nbsp;price target.
JP Morgan: Cory A. Carpenter views AppLovin&#8217;s third-quarter results as a substantial beat, with guidance for the fourth quarter surpassing analyst expectations.
Carpenter highlights the Software Platform&#8217;s impressive 17% sequential growth, driven by technology upgrades to the Axon algorithm, which significantly outpaced the typical 4%- 5% growth target.
The gaming sector fueled this strong performance, while the company&#8217;s e-commerce pilot exceeded expectations. Management now expects e-commerce to become a significant growth driver in 2025 and beyond, with resources increasingly redirected to this segment.
The fourth-quarter projections imply moderate sequential growth for the Software Platform, as costs related to vesting and expanded data capacity slightly reduce incremental margins.
Despite being optimistic about AppLovin&#8217;s mobile gaming ad monetization leadership, Carpenter remains cautious about the company&#8217;s expansion beyond gaming.
He raised the December 2025 price target from $160 to $200, noting a revised multiple of 22.5x on the estimated 2025 EBITDA, reflecting confidence in the e-commerce outlook.
This multiple, though a premium compared to most ad tech peers, still presents a discount relative to The Trade Desk, In&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) 48x, considering AppLovin&#8217;s slower growth in core gaming.
Carpenter expects fourth-quarter revenue of $1.26 billion and EPS of $1.30.
Needham: The latest results led McTernan to raise his adjusted EBITDA estimates for 2025 by 14%, reflecting a 23% year-over-year increase, with minimal assumptions for e-commerce contributions. However, management&#8217;s positive outlook on e-commerce suggests the potential for further growth.
AppLovin&#8217;s software segment has consistently outperformed, posting over 60% year-over-year growth in the past five quarters. In the third quarter, software revenue grew 66% year-over-year and 18% sequentially, primarily driven by advancements in Axon 2.0. Adjusted EBITDA for the software segment reached $653 million, up 80% year-over-year, with a margin of 78% and incremental margins of 87%.
Management attributes this success to its technology&#8217;s ability to expand the total addressable market (TAM) and increase client spending by demonstrating a high return on investment.
AppLovin&#8217;s pilot for its e-commerce advertising platform, introduced in the recent earnings call, is already yielding positive feedback. While the program is still in its early stages and expected to remain relatively small in 2024, management projects a meaningful impact by 2025. Management believes the e-commerce platform could expand into new markets, such as connected TV (CTV), potentially driving additional upside, citing customer satisfaction and strong returns.
Based on AppLovin&#8217;s third-quarter results and revised fourth-quarter projections, McTernan raised fiscal 2024 revenue and adjusted EBITDA estimates by 5% and 9%, respectively.
The 2025 revenue and adjusted EBITDA estimates also increased by 6% and 14%, considering the anticipated long-term benefits from the e-commerce platform expansion.
McTernan expects fourth-quarter revenue of $1.25 billion and EPS of $1.25.
Price Action: APP stock is up 44.1% at $242.31 at last check Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41811828/epam-q3-earnings-beats-expectations-rising-margins-ceo-flags-neoris-acquisition" target="_blank" rel="noreferrer noopener">EPAM Q3 Earnings: Beats Expectations, Rising Margins, CEO Flags NEORIS Acquisition</a></li>
</ul>

Analyst Color

Reiteration

Movers

Tech

Trading Ideas

AppLovin's High Valuation and Expansion Beyond Gaming Prompt Analyst Caution

GLJ Research analyst Gordon Johnson downgrades Sunrun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) from Hold to Sell and announces $7.78 price target.

Downgrades

GLJ Research Downgrades Sunrun to Sell, Announces $7.78 Price Target

WIIM

IMVT

Immunovant shares are trading lower after the company reported worse-than-expected Q2 EPS results.

SEDG

Solar Edge shares are trading lower after the company announced worse-than-expected Q3 financial results.

Macquarie analyst Tim Nollen maintains LiveRamp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RAMP#NYSE">RAMP</a>) with a Outperform and maintains $43 price target.

RAMP

Macquarie Maintains Outperform on LiveRamp Holdings, Maintains $43 Price Target

Offerings

Fangdd Announces $5 Million Registered Direct Offering At $0.70 Per Share, Closing Expected November 8; Proceeds To Support General Corporate Purposes

Macquarie analyst Tim Nollen maintains AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) with a Outperform and raises the price target from $150 to $270.

Macquarie Maintains Outperform on AppLovin, Raises Price Target to $270

Macquarie analyst Tim Nollen maintains Digital Turbine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPS#NASDAQ">APPS</a>) with a Neutral and lowers the price target from $3 to $2.

APPS

Macquarie Maintains Neutral on Digital Turbine, Lowers Price Target to $2

Editor: The title of the story has been updated to reflect the amount of impairment charge.
SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) shares are trading lower after the company reported third-quarter results yesterday. Revenues were $260.9 million, <a href="https://www.benzinga.com//node/41786579">missing the consensus of $269.38 million.</a>
Revenues from the solar segment were&nbsp;$247.5 million, up&nbsp;3%&nbsp;from&nbsp;$241.2 million&nbsp;in the prior quarter and down&nbsp;63%&nbsp;from&nbsp;$676.9 million&nbsp;in the same period last year.
The company shipped&nbsp;850 Megawatts (AC) of inverters and 189 MWh of batteries for PV applications in the quarter.
Adjusted gross margin&nbsp;was negative 265.4% versus a&nbsp;positive margin of&nbsp;0.2%&nbsp;in the prior quarter and compared to&nbsp;20.8%&nbsp;last year.
Adjusted operating loss stood at&nbsp;$808.1&nbsp;million versus an adjusted operating loss of&nbsp;$114.3&nbsp;million&nbsp;last quarter.
Adjusted loss per share of&nbsp;$15.33&nbsp;may not be comparable to <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">the consensus loss of&nbsp;$1.63</a>.
Operating cash flow was negative&nbsp;$63.9&nbsp;million in the quarter. As of September 30, cash, cash equivalents, bank deposits, restricted bank deposits, and marketable securities&nbsp;totaled&nbsp;$53.3&nbsp;million.
In the third quarter, SolarEdge conducted an asset valuation review, which resulted in a $1.03 billion write-down and impairment of various assets.
Outlook: For&nbsp;the&nbsp;fourth quarter, the company expects revenue of&nbsp;$180&nbsp;million &#8211; $200 million (versus&nbsp;consensus of&nbsp;$308.66 million), revenues from the solar segment of&nbsp;$170&nbsp;million &#8211; $190 million, and adjusted gross <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">margin of&nbsp;negative&nbsp;4%&nbsp;&#8211;&nbsp;0%</a>.
Investors can gain exposure to the stock via&nbsp;Invesco Solar ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAN#NYSE">TAN</a>).
Price Action: SEDG shares were down 17.3% at $12.13 premarket at the time of writing on Thursday. The stock has recouped all losses and is up 0.31% to $14.73 at the time of update as of 14.15.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/41799600" target="_blank" rel="noreferrer noopener">Nvidia Partners With AI Startup Hugging Face To Supercharge Open Source Robotics</a></li>
</ul>

Earnings

Equities

Large Cap

Guidance

SolarEdge's Tough Q3: Revenue Miss, $1 Billion Impairment Charge, Bleak Forecast & More (UPDATED)

<a href="https://www.youtube.com/watch?v=94uL1NRslpw">https://www.youtube.com/watch?v=94uL1NRslpw</a>
&nbsp;

Macro Economic Events

Global

Economics

Russia's Putin Congratulates Trump On Winning U.S. Presidential Elections; Says Desire To Restore Relations With Russia, Facilitate End Of Ukrainian Crisis Deserves Attention; Don't Think It's Wrong To Hold Call With Trump; If Some World's Leaders Seek To Restore Contacts, I'm Not Against It; We Are Ready To Speak To Trump

BTIG analyst Marvin Fong maintains MercadoLibre (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) with a Buy and lowers the price target from $2250 to $2200.

MELI

BTIG Maintains Buy on MercadoLibre, Lowers Price Target to $2200

Deep-pocketed investors have adopted a bearish approach towards Sweetgreen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in SG usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Sweetgreen. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 25% leaning bullish and 50% bearish. Among these notable options, 2 are puts, totaling $250,030, and 6 are calls, amounting to $262,457.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $40.0 to $45.0 for Sweetgreen over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Sweetgreen's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Sweetgreen's whale activity within a strike price range from $40.0 to $45.0 in the last 30 days. 
<h3>Sweetgreen Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731007036_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$3.3</td>
<td>$3.0</td>
<td>$3.29</td>
<td>$41.00</td>
<td>$163.1K</td>
<td>83</td>
<td>512</td>
</tr>
<tr>
<td>SG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$2.9</td>
<td>$2.75</td>
<td>$2.89</td>
<td>$40.00</td>
<td>$86.8K</td>
<td>2.2K</td>
<td>321</td>
</tr>
<tr>
<td>SG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$4.2</td>
<td>$4.0</td>
<td>$4.16</td>
<td>$41.00</td>
<td>$61.7K</td>
<td>390</td>
<td>3.2K</td>
</tr>
<tr>
<td>SG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$4.3</td>
<td>$4.2</td>
<td>$4.3</td>
<td>$41.00</td>
<td>$49.3K</td>
<td>390</td>
<td>2.9K</td>
</tr>
<tr>
<td>SG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$11.9</td>
<td>$11.6</td>
<td>$11.85</td>
<td>$40.00</td>
<td>$41.4K</td>
<td>301</td>
<td>35</td>
</tr>
</tbody>
</table>

<h3>About Sweetgreen</h3>
Sweetgreen Inc is a next-generation restaurant and lifestyle brand that serves healthy food at scale. It is creating plant-forward, seasonal, and earth-friendly meals from fresh ingredients and produce that prioritizes organic, regenerative, and local sourcing.
In light of the recent options history for Sweetgreen, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Sweetgreen</h3>
<ul>
<li>With a volume of 3,351,690, the price of SG is up 1.15% at $42.12. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 0 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Sweetgreen options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

Decoding Sweetgreen's Options Activity: What's the Big Picture?

Deep-pocketed investors have adopted a bullish approach towards Toast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in TOST usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Toast. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 80% leaning bullish and 10% bearish. Among these notable options, 3 are puts, totaling $139,066, and 7 are calls, amounting to $316,468.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $28.0 to $45.0 for Toast during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Toast's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Toast's whale trades within a strike price range from $28.0 to $45.0 in the last 30 days. 
<h3>Toast Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731007031_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TOST</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$12.65</td>
<td>$12.55</td>
<td>$12.55</td>
<td>$45.00</td>
<td>$79.0K</td>
<td>0</td>
<td>63</td>
</tr>
<tr>
<td>TOST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.04</td>
<td>$2.0</td>
<td>$2.03</td>
<td>$35.00</td>
<td>$61.0K</td>
<td>3.8K</td>
<td>721</td>
</tr>
<tr>
<td>TOST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$0.83</td>
<td>$0.77</td>
<td>$0.83</td>
<td>$36.00</td>
<td>$55.2K</td>
<td>83</td>
<td>3.7K</td>
</tr>
<tr>
<td>TOST</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/08/24</td>
<td>$5.25</td>
<td>$4.85</td>
<td>$5.06</td>
<td>$28.00</td>
<td>$50.5K</td>
<td>131</td>
<td>172</td>
</tr>
<tr>
<td>TOST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/22/24</td>
<td>$3.05</td>
<td>$3.05</td>
<td>$3.05</td>
<td>$31.00</td>
<td>$44.5K</td>
<td>152</td>
<td>146</td>
</tr>
</tbody>
</table>

<h3>About Toast</h3>
Toast is a us-based restaurant technology company that provides point-of-sale, payment processing, and various software services to 120,000 restaurant locations across the United States at the end of June 2024. The firm generates sales from software subscription fees, as a percentage take rate from each financial transaction it processes, from loan origination and servicing fees from its Toast Capital arm, and from hardware installation and professional services. Unlike competitors, Toast intermediates every payment transaction on its platform, processing some $126 billion in gross platform volume in 2023. The firm's product offerings span point-of-sale systems, inventory and payroll management, delivery integration, e-commerce ordering, reservation management, and loyalty programs.
<h3>Current Position of Toast</h3>
<ul>
<li>With a trading volume of 7,268,146, the price of TOST is up by 1.24%, reaching $32.54.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 0 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Toast</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $31.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Stephens &amp; Co. persists with their Equal-Weight rating on Toast, maintaining a target price of $30. 
&#x2A; Maintaining their stance, an analyst from Goldman Sachs continues to hold a Buy rating for Toast, targeting a price of $33. 
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on Toast, maintaining a target price of $33. 
&#x2A; Maintaining their stance, an analyst from Baird continues to hold a Neutral rating for Toast, targeting a price of $30. 
&#x2A; An analyst from Deutsche Bank has decided to maintain their Hold rating on Toast, which currently sits at a price target of $30. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Toast with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

TOST

Looking At Toast's Recent Unusual Options Activity

Craig-Hallum analyst Jeremy Hamblin maintains Kura Sushi USA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRUS#NASDAQ">KRUS</a>) with a Buy and raises the price target from $85 to $120.

KRUS

Craig-Hallum Maintains Buy on Kura Sushi USA, Raises Price Target to $120

Barrington Research analyst Alexander Paris maintains Strategic Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRA#NASDAQ">STRA</a>) with a Outperform and maintains $135 price target.

STRA

Barrington Research Maintains Outperform on Strategic Education, Maintains $135 Price Target

BTIG analyst Marvin Fong maintains Upwork (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPWK#NASDAQ">UPWK</a>) with a Buy and raises the price target from $14 to $16.

UPWK

BTIG Maintains Buy on Upwork, Raises Price Target to $16

In a report released today, Edward White from H.C. Wainwright maintained a Hold rating on 60 Degrees Pharmaceuticals, Inc. (SXTP – Research Report)...

H.C. Wainwright Keeps Their Hold Rating on 60 Degrees Pharmaceuticals, Inc. (SXTP)

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
60 Degrees Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/sxtp-stock-quote/">SXTP</a>) stock is gaining on Monday after the specialty pharmaceutical company <a href="https://finance.yahoo.com/news/60-degrees-pharma-provides-university-131200159.html">announced an agreement</a> with the University of Kentucky.



This agreement will have the University of Kentucky conducting a Phase IIb clinical trial of SJ733. This is a drug candidate in development by 60 Degrees Pharmaceuticals for the treatment of vivax malaria.



This study will cover the use of SJ733 alongside tafenoquine to treat vivax malaria. The information from this study will also be applied to 60 Degrees Pharmaceuticals New Drug Application (NDA) for the drug.



Dr. R. Kip Guy, the principal investigator of the study, said the following about it:




&ldquo;Innovations in treating P. vivax malaria, which infects an estimated 14 million people a year, have been limited in recent decades. The upcoming study of SJ733 combined with tafenoquine has the potential to pave the way for very meaningful improvement in malaria treatment around the world.&rdquo;




<h2>What This Means for SXTP Stock</h2>



This new clinical trial news has SXTP stock heading higher on Monday with heavy trading of the shares. That has more than 11.9 million shares changing hands as of this writing. To put that in perspective, the company&rsquo;s daily average trading volume is about 448,000 shares.



SXTP stock is up 28.9% as of Monday afternoon.



There are even more stock market stories traders are going to want to read about below!



We have all of the hottest stock market news ready to go on Monday! A few examples include what&rsquo;s going on with shares of Draganfly&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/dpro-stock-quote/">DPRO</a>), KeyBank (NYSE:<a href="https://investorplace.com/stock-quotes/key-stock-quote/">KEY</a>) and Archer Aviation&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/achr-stock-quote/">ACHR</a>) stock today. All of this news is available at the following links!



<h2>More Monday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/08/why-is-draganfly-dpro-stock-up-37-today/">Why Is Draganfly (DPRO) Stock Up 37% Today?</a></li>



<li><a href="https://investorplace.com/2024/08/key-stock-surge-alert-whats-going-on-with-keycorp-shares-today/">KEY Stock Surge Alert: What&rsquo;s Going On With KeyCorp Shares Today?</a></li>



<li><a href="https://investorplace.com/2024/08/achr-stock-3-things-for-investors-to-know-about-the-370-million-stellantis-deal/">ACHR Stock: 3 Things for Investors to Know About the $370 Million Stellantis Deal</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/why-is-60-degrees-pharmaceuticals-sxtp-stock-up-29-today/">Why Is 60 Degrees Pharmaceuticals (SXTP) Stock Up 29% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is 60 Degrees Pharmaceuticals (SXTP) Stock Up 29% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
60 Degrees (NASDAQ:<a href="https://investorplace.com/stock-quotes/sxtp-stock-quote/">SXTP</a>) just reported results for the second quarter of 2024.<ul><li>60 Degrees reported earnings per share of -$4.23. This was below the analyst estimate for EPS of -23 cents.</li><li>The company reported revenue of $124,972.</li><li>This was 37.51% worse than the analyst estimate for revenue of $200,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/sxtp-stock-earnings-60-degrees-for-q2-of-2024/">SXTP Stock Earnings: 60 Degrees Misses EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

SXTP Stock Earnings: 60 Degrees Misses EPS, Misses Revenue for Q2 2024

H.C. Wainwright Sticks to Their Hold Rating for 60 Degrees Pharmaceuticals, Inc. (SXTP)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Outlook Therapeutics (OTLK – Research Report), 60 ...

Analysts Offer Insights on Healthcare Companies: Outlook Therapeutics (OTLK), 60 Degrees Pharmaceuticals, Inc. (SXTP) and Gritstone Oncology (GRTS)

60 Degrees Pharmaceuticals GAAP EPS of -$4.23

Earnings week ahead: Zoom, Lowe's, Target, Baidu, XPeng, Zim Integrated and more

60 Degrees Pharmaceuticals to raise $4M via private placement; shares fall

H.C. Wainwright analyst Edward White maintained a Hold rating on 60 Degrees Pharmaceuticals, Inc. (SXTP – Research Report) today. The company's sha...

H.C. Wainwright Reaffirms Their Hold Rating on 60 Degrees Pharmaceuticals, Inc. (SXTP)

Warning: SXTP is at high risk of performing badly

ASND

AYRO

BIDU

BILI

BTBT

CARA

CATO

COTY

CSIQ

CTXR

ESTC

FORD

FUTU

GGAL

GRTS

IMMR

INTU

JKHY

KEYS

MBRX

MMAT

NNDM

NNOX

NTES

OTLK

PANW

PTON

ROST

SEEL

SNOW

SNPS

SXTP

URBN

VIPS

WDAY

WKHS

WOLF

XPEV

Health Care

Press Releases

General

60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment

60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study

Contracts

60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support

60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split

60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study

60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results

60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements

60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Financing

60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch

Comments

60 Degrees

60 Degrees (SXTP) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL